Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection

Author:

Dyall Julie,Coleman Christopher M.,Hart Brit J.,Venkataraman Thiagarajan,Holbrook Michael R.,Kindrachuk Jason,Johnson Reed F.,Olinger Gene G.,Jahrling Peter B.,Laidlaw Monique,Johansen Lisa M.,Lear-Rooney Calli M.,Glass Pamela J.,Hensley Lisa E.,Frieman Matthew B.

Abstract

ABSTRACTOutbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets forin vivostudies as well as incorporation into ongoing clinical studies.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference48 articles.

1. WHO. 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/index.html.

2. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia;Zaki;N. Engl. J. Med.,2012

3. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans;The WHO MERS-Cov Research Group;PLoS Curr.,2013

4. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26;Lu;Nature,2013

5. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC;Raj;Nature,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3